Anons—lots of juicy shit in here that oddly reflects what’s happening today…below are definitions used throughout the link below.

> https://file.wikileaks.org/file/avian-flu-chair-text-2008.pdf

WORLD HEALTH ORGANIZATION

INTERGOVERNMENTAL MEETING ON PANDEMIC INFLUENZA PREPAREDNESS: SHARING OF INFLUENZA VIRUSES AND ACCESS TO VACCINES AND OTHER BENEFITS OPEN-ENDED WORKING GROUP

PANDEMIC INFLUENZA PREPAREDNESS: MULTILATERAL FRAMEWORK FOR THE SHARING OF INFLUENZA VIRUSES AND ACCESS TO VACCINES AND OTHER BENEFITS

“Essential regulatory laboratories” means influenza laboratories, located in national regulatory agencies, and which have a critical role at the global level for developing, regulating and standardizing influenza vaccines. In this capacity they work closely with WHO and industry.

Influenza virus with human pandemic potential” designates any influenza virus that has been found to infect a human and that has a haemagglutinin antigen that is distinct from those in seasonal influenza viruses so as to indicate that the virus has potential to be associated with pandemic spread within human populations.

>“Pandemic influenza preparedness vaccine virus” or “PIP vaccine virus” designates any wild-type influenza virus, influenza reference virus, high-growth reassortant virus, WHO-recommended virus for vaccine use or other influenza virus material generated from H5N1 or other influenza virus with human pandemic potential provided to vaccine manufacturers for the purposes of developing a prototype pandemic, pre-pandemic or pandemic influenza vaccine.

“Clinical specimens” means materials collected from humans, generally in order to confirm a diagnosis. For influenza, most commonly, clinical specimens are taken from the respiratory tract (for example, swabs and aspirated fluid) but they can be from other locations. Clinical specimens can be frozen and stored for later use.

>“WHO Collaborating Centres” specialising in influenza or “WHO CCs” means animal or human influenza laboratories designated by WHO and fully supported by national authorities to perform certain roles within the [WHO Network], and which have accepted formal Terms of Reference from WHO. In general, they differ from National Influenza Centres and WHO H5 Reference Laboratories in having global responsibilities and more extensive technical capacities. As of May 2008, WHO CCs included the WHO Collaborating Centres for Reference and Research on Influenza in London, Melbourne and Tokyo, the WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza in Atlanta and the WHO Collaborating Centre for Studies on the Ecology of Influenza in Animals in Memphis.

“WHO H5 Reference Laboratories” means influenza laboratories that have been designated by WHO in order to strengthen national and regional capacity for reliably diagnosing H5 virus infection until this capacity is more widespread.

[“WHO Network”] means the international network of influenza laboratories, coordinated by WHO, that conduct year-round surveillance of influenza, assessing the risk of pandemic influenza and assisting in preparedness measures. The [WHO Network] comprises National Influenza Centres, WHO Collaborating Centres on Influenza, WHO H5 Reference Laboratories and essential regulatory laboratories.

Other Terms

“Multilateral Framework” means the system and mechanisms adopted and agreed by Member States to govern the sharing of H5N1 and other influenza viruses with human pandemic potential and the benefits resulting from their use. Parties and/or entities contributing to and participating in the Multilateral Framework include but are not limited to: WHO Member States, the [WHO Network] and Influenza Vaccine Manufacturers.

“WHO MEMBER STATES”. The 193 States party to the WHO Constitution.

>>8912807

“Wild-type influenza viruses” (synonym: virus isolates) means influenza viruses that have been cultured either in eggs or cells (i.e. isolated) directly from clinical specimens and have not been purposefully modified.

SHARING OF H5N1 AND OTHER INFLUENZA VIRUSES WITH HUMAN PANDEMIC POTENTIAL

5.1 General Provisions

5.1.1 With the objective of improving pandemic influenza preparedness and strengthening global public health security and in consideration of the multilateral benefit sharing system being established under this Framework, Member States agree to routinely provide clinical specimens or viruses from all human cases of H5N1 and other influenza viruses of human pandemic potential in a timely fashion:

a) to the WHO Collaborating Centre for Influenza or H5 Reference Laboratory of their choice, and

(b) through those laboratories to other laboratories in the [WHO Network], vaccine, diagnostic and pharmaceutical manufacturers and public health researchers, for the purposes of: full virus characterization, pandemic risk assessment, the development and validation of diagnostics and pharmaceuticals, the development of pandemic influenza preparedness vaccine viruses and the development and production of vaccines.

[5.1.2 Member States may also provide clinical specimens from human cases of H5N1 and other influenza viruses of human pandemic potential directly to any other party or body on a bilateral or multilateral basis provided that this does not preclude the same materials being provided to the WHO Collaborating Centres and/or H5 reference laboratories under this Framework.]

5.3 Standard Material Transfer Agreement

5.3.1 General

The transfer of PIP biological materials into, within and out of the [WHO Network] shall be governed by a Standard Materials Transfer Agreement containing the following elements. The Standard 8Materials Transfer Agreement shall be standardized, universal and globally applicable to all transfers of biological materials and not subject to further negotiation.

5.3.2 Traceability

A. National Influenza Centres and other laboratories designated by Member States to provide clinical specimens from human cases of H5N1 and other influenza viruses of human pandemic potential shall register those specimens in the traceability mechanism as PIP biological materials.

B. As a condition of receiving PIP biological materials, all organizations within and outside the [WHO Network] shall register receipt of the PIP biological materials through the traceability mechanism and shall comply with any other data provision requirements of the traceability and associated reporting mechanisms.

C. Organizations outside the [WHO Network] receiving PIP biological materials shall not further transfer the materials outside the [WHO Network] without the prior informed consent of the Member State where the clinical specimens were collected and the [WHO Network] laboratory that provided the materials, except insofar as the materials have been transformed to become an indivisible element of a vaccine, diagnostic or pharmaceutical product.

5.3.12 Benefits

PIP biological materials are provided to the [WHO Network] laboratories, vaccine, diagnostic and pharmaceutical manufacturers and public health researchers with the objective of improving pandemic influenza preparedness and strengthening global public health security. In consideration of this, and recalling Resolution WHA60.28, the multilateral benefit sharing system set out in the WHO Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits aims to improve access for developing and least developed countries, especially affected countries, to vaccines and other benefits from the sharing of H5N1 and other influenza viruses of human pandemic potential.

1. MULTILATERAL BENEFIT SHARING SYSTEM

6.1 Acknowledging the contribution of countries affected by H5N1 and other influenza viruses with human pandemic potential, particularly developing countries, in collecting clinical specimens and sharing viruses with the [WHO Network] and recognizing the global and indivisible nature of the pandemic threat, Member States agree to establish a multilateral system for the sharing of benefits arising from the use of H5N1 and other influenza viruses with human pandemic potential.

6.3 [WHO Network] laboratories shall make available to the WHO Secretariat ><-who is this????

Provision of diagnostic tests and materials

6.4 WHO Collaborating Centres [and H5 Reference Laboratories] shall make available to National Influenza Centres and other laboratories designated by Member States to provide clinical specimens, without charge, supplies of noncommercial diagnostic test materials and reagents for the identification and characterization of clinical specimens of influenza.